Bladder Cancer Matters podcast

Can Gene Therapy Change Bladder Cancer Treatment?

0:00
19:25
Rewind 15 seconds
Fast Forward 15 seconds

What if a new approach to gene therapy could give people with bladder cancer more treatment options while making treatment easier to manage?

In this episode of Bladder Cancer Matters, host Rick Bangs welcomes Anthony Cheung, co-founder of enGene Therapeutics, to explore an innovative investigational treatment for patients with high-risk non-muscle invasive bladder cancer who no longer respond to BCG therapy. Discover how enGene is using non-viral gene delivery technology to help the body's immune system recognize and attack bladder cancer cells.

Cheung shares the surprising conversation that inspired enGene's entry into bladder cancer research, explains how its investigational therapy works and discusses promising directions in ongoing clinical trials. You'll also hear why making treatments more convenient, accessible and less burdensome for patients is central to the company's mission. For patients, caregivers and anyone interested in the future of bladder cancer treatment, this conversation offers a fascinating look at the science behind potential new treatment options.

More episodes from "Bladder Cancer Matters"